Voy

What Voy does

Voy (legal entity Menwell Limited) is a UK-headquartered digital health platform that delivers vertically integrated telehealth consultations, prescription medications, at-home and in-clinic blood diagnostics, and AI-assisted patient support across four core treatment verticals: weight loss (GLP-1 medications including Mounjaro, Wegovy, and the Wegovy Pill oral semaglutide), menopause and perimenopause care (HRT, testosterone, vaginal treatments, supplements, and skincare), testosterone replacement therapy for men, and hair loss treatments. The company operates a GPhC-registered in-house pharmacy (Manual Pharmacy, registration 2063362) that dispenses and couriers prescriptions directly to patients, a Voy companion mobile app for progress tracking and clinician communication, an AI-powered 24/7 chatbot named Joy, and the Do Health preventative health sub-brand co-founded with Dr. Rangan Chatterjee. Voy is regulated by the MHRA and CQC in the UK, holds DCB0129 clinical governance compliance, and serves more than 1.5 million cumulative patients across the UK, Germany, Brazil, and India (the latter via the June 2026 acquisition of EarlyFit). The business model is primarily direct-to-consumer subscription-based with monthly recurring revenue per treatment pathway, supplemented by NHS and public sector commissioning contracts acquired via the 2025 Morelife acquisition in Manchester and Sheffield, with annualised revenue reported at approximately $675M growing around 130% year-over-year.

Name

Voy

Legal name

Menwell Limited

Website

https://joinvoy.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Voy is a UK-based digital health and telemedicine platform offering subscription-based online consultations, prescription medications, and home-delivered treatments for weight loss, menopause, low testosterone, and hair loss, serving over 1 million patients across the UK, Germany, Brazil, and India.

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices8 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D, Supply Chain

Revenue model

1. Prescription Medications: Revenue from prescribing GLP-1 medications (Mounjaro, Wegovy, Wegovy Pill), Saxenda, Orlistat, testosterone treatments, HRT, and other prescription medications through their pharmacy. Patients pay subscription fees for ongoing treatment access.
2. Telehealth Consultations: Fees from video and asynchronous consultations with clinicians for weight loss, menopause, testosterone, and hair loss treatments. Includes specialist consultations and ongoing care management.
3. Supplements and Skincare: Sale of Voy-branded supplements and skincare products (estriol skin cream) for menopause patients
4. NHS/Public Sector Contracts: Revenue from public healthcare contracts following Morelife acquisition, serving NHS obesity patients in specified regions

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Voy operates a digital health platform providing telehealth consultations and home-delivered prescription medications across weight loss (GLP-1 medications such as Mounjaro, Wegovy), menopause care (HRT, testosterone), testosterone replacement therapy, and hair loss treatments. The service combines online medical questionnaires, video and asynchronous clinician consultations, an integrated GPhC-registered pharmacy (Manual Pharmacy), at-home blood testing, and a companion mobile app with 24/7 AI-powered support (Joy).

Product overview

Voy is a digital health platform positioned as a 'Proactive Companion for Healthy Living' that provides clinically proven treatments across multiple health categories. The platform operates as a unified ecosystem combining telehealth consultations, prescription medications, diagnostic testing, and AI-powered support. The core product portfolio includes four main treatment pathways: Weight Loss (offering GLP-1 medications like Mounjaro and Wegovy), Menopause (HRT, testosterone, vaginal treatments, supplements, and skincare), Testosterone Replacement Therapy (with at-home blood testing and personalised plans), and Hair Loss (finasteride, minoxidil, vitamins, and comprehensive plans). Supporting the treatment pathways are the Do Health mobile app (a preventive health companion co-founded with Dr Rangan Chatterjee), the Voy companion app for patient progress tracking, and utility tools including BMI and TDEE calculators. The platform integrates 24/7 AI-powered support, at-home diagnostic testing, and clinical oversight from UK-based medical experts, all delivered through video and asynchronous consultations. The company rebranded from MANUAL to Voy in 2025 and has expanded internationally into Brazil, Germany, and India.

Differentiator

Problem solved

Functional benefit

Brands

• Do Health: Mobile-first preventative health product co-founded with Dr Rangan Chatterjee, combining regular blood tests, longitudinal health data, behaviour-change principles and AI personalisation to help people make better lifestyle decisions.
• Manual Pharmacy

Products and services

• Voy Weight Loss Clinically proven digital weight loss programme offering GLP-1 medications (Mounjaro, Wegovy, Wegovy Pill, Saxenda, Orlistat) with claims of up to 23% body weight loss, delivered via telehealth consultations and home delivery.
• Voy Menopause Digital menopause care providing hormone replacement therapy (HRT), testosterone treatment, vaginal oestrogen treatments, supplements and skincare, delivered via video and asynchronous consultations with specialist clinicians.
• Voy Testosterone Replacement Therapy (TRT) Testosterone replacement therapy for men with low testosterone, including at-home blood testing, personalised treatment plans, and ongoing monitoring, with an average 296% increase in total testosterone reported among members.
• Voy Hair Loss Hair restoration service for men and women offering treatments including Complete Hair Loss Plan, Finasteride Plan, Minoxidil Plan, Hair Vitamins, and Power Shampoo.
• Do Health Mobile-first preventative health app co-founded with Dr Rangan Chatterjee that combines regular blood tests, longitudinal health data, behaviour-change science, and AI personalisation to help users make better lifestyle decisions over time.
• At-Home Blood Tests Standalone diagnostic testing service offering at-home and in-clinic blood tests for testosterone levels, menopause monitoring, and general health assessments, including Women's Midlife (MOT) blood test and Monitor HRT blood test.
• Voy Supplements Voy-branded supplements designed for menopause support, sold as part of the menopause treatment ecosystem.
• Estriol Skin Cream Topical skincare treatment for menopause symptoms, part of the menopause treatment portfolio.

Quantifiable outcome

• Patients lose 5 times more weight with Voy than with diet and exercise alone
• +7 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• EarlyFitcoreStrategic or Co-development Partner · 8 June 2026100% acquisition of EarlyFit, one of India's leading online weight loss platforms. Voy's entry vehicle into India's 150 million obese population market. Brings local expertise and platform to Voy's India expansion.
• MorelifecoreStrategic or Co-development Partner · 1 January 2025Acquired Morelife, which has been operating in the NHS for 25 years as one of the leading obesity providers. Expands Voy into public sector commissioning contracts.
• Imperial College LondoncoreStrategic or Co-development PartnerAcademic partnership for clinical research, innovation, and validation of digital health treatments. Listed as collaborator on Voy's research initiatives.
• University of OxfordcoreStrategic or Co-development PartnerAcademic partnership for clinical research and evidence-based obesity and metabolic health care development.
• University of BirminghamcoreStrategic or Co-development PartnerAcademic partnership contributing to clinical research initiatives and validation of treatment outcomes.
• Universidade Federal de Minas Gerais (UFMG)minorStrategic or Co-development PartnerInternational academic partnership in Brazil for clinical research collaboration.
• Ulster UniversityminorStrategic or Co-development PartnerAcademic partnership for clinical research and innovation in digital health.
• Dr Rangan Chatterjee / Do HealthcoreStrategic or Co-development PartnerCo-founded Do Health, a mobile-first preventative health app powered by blood tests and AI personalisation. Dr Chatterjee is a prominent BBC presenter and lifestyle medicine expert.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Numan: UK D2C digital health platform offering treatments for hair loss, erectile dysfunction, TRT and weight management via subscription. Closest UK peer by category mix and target demographic (men's health-led D2C subscription).
• MedExpress: UK-based online pharmacy and telehealth provider focused on prescription weight-loss treatments and men's health. Co-defendant with Voy in the ASA ruling, indicating identical DTC prescription-medicine model.
• Zava: UK/European online clinic offering telehealth consultations and prescriptions for weight loss (GLP-1s), men's health, and women's health. Most directly comparable competitor; was jointly named in the ASA affiliate ban alongside Voy.
• UK Meds Direct: UK online pharmacy providing prescription medications including weight-loss injections and men's health treatments. Direct competitor on the GLP-1 supply and prescribing side; also named in the ASA enforcement.

Emerging players

• Form Health: US obesity-care telehealth platform providing physician-supervised weight-loss treatment including GLP-1 prescriptions. Focused exclusively on obesity, offering a narrower but deeper specialty competitor to Voy's weight-loss vertical.
• Eucalyptus: Australia-based digital health platform operating multiple telehealth brands including Juniper (weight loss), Pilot (men's health) and Kin Fertility. Comparable multi-brand D2C prescription model in an English-speaking regulatory environment.
• Thirty Madison: US D2C telehealth platform with category-specific brands (Hers, Keeps, Cove, Nurx) covering women's health, hair loss and chronic conditions. Comparable category-led vertical strategy with strong D2C subscription DNA.

Broad incumbents

• WeightWatchers (WW International): Publicly listed weight-management company that has pivoted into GLP-1 prescribing (WW Clinic) and bundled telehealth subscriptions. Comparable D2C subscription weight-loss model with established consumer brand, though not vertically integrated into pharmacy operations.
• LloydsPharmacy Online Doctor: Online arm of one of the UK's largest pharmacy chains offering telehealth prescriptions for weight loss, men's health, women's health and travel medicine. Incumbent peer with high brand trust but less integrated platform than Voy.
• Hims & Hers Health: US-listed D2C telehealth platform offering prescription treatments across weight loss, hair loss, TRT and women's health via subscription. Same vertically integrated model as Voy but at greater scale and public-market valuation benchmark.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Joinvoyindia
• Instagraminstagram.com/joinvoy
• LinkedInlinkedin.com/company/joinvoy

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Voy